Source: Virtual Congress 2020 – Cystic fibrosis
Disease area: Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
V. Shmarin ( Moscow, Russian Federation), D. Pukhalskaya ( Moscow, Russian Federation), T. Kuznetsova ( Moscow, Russian Federation), S. Krasovsky ( Moscow, Russian Federation), S. Semykin ( Moscow, Russian Federation), M. Usacheva ( Moscow, Russian Federation), G. Shmarina ( Moscow, Russian Federation), V. Alioshkin ( Moscow, Russian Federation). Midregional proadrenomedullin in patients with cystic fibrosis lung disease: a pilot study. 2772

Member's Comments

No comment yet.

Related content which might interest you: The diagnostic value of N-terminal pro-C-type natriuretic peptide in COPD patients with pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension in lung disease Year: 2015 N-terminal pro-brain natriuretic peptide is a useful prognostic marker in patients with pulmonary hypertension and renal insufficiency Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013 Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease Source: Eur Respir J, 57 (2) 2003079; 10.1183/13993003.03079-2020 Year: 2021 Aspergillus pulmonary disease in cystic fibrosis (CF) patients: multicentre perspective observational study based on new diagnostic tests to evaluate the prognostic value on the CF disease Source: Virtual Congress 2021 – Adult cystic fibrosis Year: 2021 Prognostic value of serum N-terminal brain natriuretic peptide type B for pulmonary hypertension among patients with usual interstitial pneumonia and sarcoidosis Source: Annual Congress 2007 - Pulmonary vascular involvement in smoking and respiratory diseases Year: 2007 Risk factors for lung disease progression in children with cystic fibrosis; a longitudinal cohort study Source: International Congress 2017 – Cystic fibrosis: treatments and monitoring Year: 2017 Diaphragm ultrasound in patients with interstitial lung disease (ILD): a prospective study. Source: Virtual Congress 2021 – Exercise tolerance, supportive care and more in non-pulmonary fibrosis interstitial lung diseases Year: 2021 Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension Source: Eur Respir J 2010; 35: 95-104 Year: 2010 The utility of brain natriuretic peptide in patients with stable chronic lung diseases Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH Year: 2012 Prospective evaluation of cardio-metabolic comorbidities in a cohort of patients with non-cystic fibrosis bronchiectasis. Source: Virtual Congress 2020 – Interesting clinical problems for the respiratory physician Year: 2020 Final analysis of RECAP, an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment I Year: 2016 Diffusing lung capacity and pro-brain natriuretic peptide in patients with limited cutaneous form of systemic sclerosis at risk for pulmonary hypertension Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Lung ultrasound in children with interstitial lung disease: a pilot study. Source: Virtual Congress 2020 – Tip the hat to paediatric bronchology Year: 2020 A cohort of patients with a progressive fibrosing phenotype of interstitial lung disease (PF-ILD) other than idiopathic pulmonary fibrosis (IPF): the PROGRESS study Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020 Autopsy findings in 42 consecutive patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2008; 32: 170-174 Year: 2008 The experience of patients with cystic fibrosis during pulmonary exacerbations: a mixed-method study Source: International Congress 2017 – Nursing practice across respiratory care pathways Year: 2017 Diagnostic value of N-terminal pro-brain natriuretic peptide in patients with COPD with chronic hypoxemic respiratory failure. Source: Virtual Congress 2020 – COPD and the impact of comorbidities Year: 2020 Early markers of cystic fibrosis structural lung disease: follow-up of the ACFBAL cohort Source: Eur Respir J, 55 (4) 1901694; 10.1183/13993003.01694-2019 Year: 2020 Is lung function worsening during adolescence in cystic fibrosis? A retrospective study Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new aspects of risk factors, treatments and diagnosis Year: 2012 The role of amino-terminal pro-brain natriuretic peptide (NT-proBNP in clinical evaluation of patient with acute exacerbation chronic obstructive pulmonary disease Source: International Congress 2014 – ICU outcomes, sepsis and infections Year: 2014